Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Acne Infection01:27

Acne Infection

Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unmasking contact sensitization in rosacea: Evidence from a systematic review and meta-analysis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Allergic contact dermatitis to sorbitan sesquioleate in a zinc oxide paste.

Italian journal of dermatology and venereology·2026
Same author

Case Report: Occupational bullous dermatosis: first report of skin lesions induced by PVC welding fume in a manufacturing worker.

Frontiers in immunology·2025
Same author

Cutaneous Infections Caused by <i>Trichophyton indotineae</i>: Case Series and Systematic Review.

Journal of clinical medicine·2025
Same author

Occupational Airborne Allergic Contact Dermatitis Caused by a Metal-Working Fluid Containing Methylisothiazolinone.

Contact dermatitis·2024
Same author

Crusted scabies diagnosed in an atopic patient during treatment with upadacitinib.

European journal of dermatology : EJD·2024

Related Experiment Video

Updated: Jul 19, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Emerging drugs for psoriasis.

Gino A Vena1, Nicoletta Cassano

  • 12nd Dermatology Clinic, University of Bari, Bari, Italy. g.vena@dermatologia.uniba.it

Expert Opinion on Emerging Drugs
|October 27, 2006
PubMed
Summary

Psoriasis treatments are evolving beyond targeting immune cells and cytokines like TNF-alpha and IFN-gamma. New drugs focus on immunological tolerance and intracellular targets for chronic inflammatory skin disease.

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Psoriasis is a chronic, immune-mediated inflammatory skin disease.
  • Abnormal keratinocyte differentiation and proliferation characterize psoriasis.
  • Both innate and adaptive immune responses, particularly Type 1 T cells and their cytokines, are implicated in its pathogenesis.

Purpose of the Study:

  • To review current and emerging drug development for psoriasis.
  • To highlight therapeutic strategies targeting immune responses and intracellular pathways.

Main Methods:

  • Review of preclinical and clinical drug development for psoriasis.
  • Focus on drugs targeting T cell activation, proliferation, trafficking, and effector cytokines (e.g., TNF-alpha, IFN-gamma).
  • Exploration of novel approaches including immunological tolerance induction and small molecule/oligonucleotide inhibitors of specific molecular targets.

Related Experiment Videos

Last Updated: Jul 19, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Main Results:

  • Several drugs targeting immune responses are in development.
  • Anti-TNF-alpha biologics have shown efficacy.
  • IFN-gamma inducers and drugs targeting intracellular events are also promising.
  • Emerging therapies include those inducing immunological tolerance.

Conclusions:

  • The immunopathogenesis of psoriasis is complex, involving multiple immune pathways.
  • A variety of novel therapeutic agents are under investigation for psoriasis.
  • Current research interest in psoriasis drug development is substantial, with diverse strategies being explored.